When Terlipressin Should Be Used
Terlipressin is the preferred first-line vasoconstrictor for treating hepatorenal syndrome-acute kidney injury (HRS-AKI) in patients with cirrhosis who are not in shock, administered as either IV bolus (1 mg every 4-6 hours) or continuous infusion, always in combination with albumin. 1, 2
Primary Indication: HRS-AKI
Terlipressin is specifically indicated for HRS-AKI, defined by:
- Cirrhosis with ascites
- Serum creatinine ≥2.25 mg/dL with rapid progression
- No sustained improvement after 48 hours of diuretic withdrawal and volume expansion with albumin (1 g/kg day 1, then 20-40 g/day)
- Exclusion of other causes of AKI 3
The FDA approval was based on the CONFIRM trial showing 29% HRS reversal with terlipressin versus 16% with placebo (p=0.012) 3.
Patient Selection: Who Benefits Most
Predictors of response that should guide your decision to initiate therapy 1:
- Bilirubin ≤10 mg/dL (170 μmol/L)
- Serum creatinine ≤5 mg/dL (440 μmol/L)
- ACLF grade 0-2 (NOT grade 3)
- Increase in MAP ≥5 mmHg with treatment
Early initiation is critical—ACLF grade is the major determinant of response, with ACLF-2 and -3 having significantly lower probability of benefit 1.
Critical Contraindications and Warnings
Do NOT use terlipressin in patients with 1, 3:
- Shock requiring vasopressors (use norepinephrine instead)
- ACLF grade 3 with respiratory failure (FDA black box warning)
- Baseline serum creatinine >7.0 mg/dL
- Known ischemic conditions (coronary artery disease, peripheral vascular disease)
- Baseline hypoxemia or significant respiratory disease
- Uncontrolled bacterial infection or sepsis
The CONFIRM trial showed increased respiratory failure in ACLF-3 patients (likely from increased afterload in cirrhotic cardiomyopathy combined with aggressive albumin), leading to the FDA warning 1. A post-hoc analysis excluding ACLF-3 and SCr ≥5 mg/dL showed no increased respiratory failure risk (11% vs 7%, p=0.360) 4.
Dosing Protocol
Initial dose: 1 mg IV every 6 hours (as bolus over 2 minutes OR continuous infusion) 1, 2, 3
Dose escalation: If serum creatinine decreases <30% by Day 4, increase to 2 mg every 6 hours (maximum 12 mg/day) 1, 3
Discontinuation criteria: If serum creatinine remains at or above baseline on Day 4 with maximum tolerated dose, stop therapy 2
Duration: Maximum 14 days 1, 3
Continuous infusion achieves same efficacy as bolus dosing with lower total daily dose and fewer side effects 1. Real-world data shows 75% of clinicians use continuous infusion 5.
Always Combine with Albumin
Albumin is mandatory: 1 g/kg on day 1 (maximum 100 g), then 20-40 g/day as clinically indicated 2, 3. However, monitor closely for volume overload—the respiratory complications in ACLF-3 patients were partly attributed to overly aggressive albumin administration 1.
When NOT to Use: Common Pitfall
Real-world data shows terlipressin is frequently used off-label for non-HRS AKI 5. In a prospective study of 243 patients receiving terlipressin, only 50% had HRS-AKI; 17% had acute tubular necrosis (ATN), 25% hypovolemic AKI. AKI resolution in ATN was only 29% versus 51% in HRS-AKI 5. ATN independently predicted lack of response (OR=2.77) and 28-day mortality. The risks likely outweigh benefits in ATN.
Alternative When Terlipressin Unavailable
If terlipressin is not available, norepinephrine is non-inferior for HRS-AKI reversal 1, 2. Meta-analyses confirm equivalent efficacy 1.
Norepinephrine is the first-line choice when shock is present 1.
Midodrine (5-15 mg PO every 8 hours) plus octreotide (100-200 μg every 8 hours) may be considered but has low efficacy 2.
Monitoring and Side Effects
- Ischemic complications: Angina, arrhythmias, digital ischemia
- Respiratory failure: Especially in patients with baseline hypoxemia, cardiac dysfunction, or ACLF-3
- GI symptoms: Abdominal pain, diarrhea (from intestinal motility stimulation)
- Volume overload: From albumin administration
Response definition: Serum creatinine <1.5 mg/dL or return to within 0.3 mg/dL of baseline 2
Impact on Transplant Candidacy
All patients with HRS-AKI should be urgently evaluated for liver transplantation regardless of terlipressin response 2. Responders have better post-transplant survival with lower rates of chronic kidney disease and need for renal replacement therapy 6.
The MELD score paradox: Successful treatment lowers creatinine and thus MELD score, potentially disadvantaging wait-list position. Many countries (except the US) have implemented MELD lock strategies to preserve pre-treatment MELD scores 6.
Recurrence Management
HRS-AKI may recur after treatment discontinuation and should be retreated 2. Patients requiring long-term terlipressin for recurrent HRS should be treated as needing renal replacement therapy when assessing transplant priority 6.
Survival Benefit Nuance
While terlipressin trials have not shown overall survival improvement, every 1 mg/dL drop in serum creatinine reduces mortality risk by 27% 1. Responders who achieve complete HRS reversal have significantly better survival than non-responders 1. In the AARC-defined ACLF population, terlipressin was more effective than norepinephrine in both reversing HRS and improving 28-day survival 1.